Goldenrod Therapeutics raised $6.5 million to advance therapies for the treatment of Friedreich’s ataxia, a rare neurodegenerative disorder.
Goldenrod Therapeutics raised $6.5 million to advance therapies for the treatment of Friedreich’s ataxia, a rare neurodegenerative disorder.